PYXS
Pyxis Oncology, Inc.
Price Chart
Latest Quote
$2.03
+0.13 (+6.84%)
Current Price
| Previous Close | $1.90 |
| Open | $1.90 |
| Day High | $2.07 |
| Day Low | $1.90 |
| Volume | 668,652 |
Stock Information
| Shares Outstanding | 63.36M |
| Total Debt | $18.26M |
| Cash Equivalents | $41.02M |
| Revenue | $13.86M |
| Net Income | $-81.73M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $128.61M |
| EPS (TTM) | $-1.30 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $105.85M |
| Sales | $13.86M |
| Income | $-81.73M |
| Book/sh | $0.49 |
| Cash/sh | $0.65 |
| Employees | 56 |
Financial Ratios
| Quick Ratio | 2.48 |
| Current Ratio | 2.76 |
| Debt/Eq | 58.39 |
Returns & Margins
| ROA | -51.94% |
| ROE | -121.66% |
| Gross Margin | 82.77% |
| Operating Margin | -600.20% |
Ownership
| Insider Ownership | 22.13% |
| Institutional Ownership | 33.86% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.64 |
| P/S | 9.28 |
| P/B | 4.11 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $7.00 |
Technical Indicators
| SMA20 | $1.77 |
| SMA50 | $1.88 |
| SMA200 | $2.30 |
| RSI | 66.20 |
| ATR | 0.1584 |
| Shares Float | 40.41M |
| Short Float | 3.72% |
| Short Ratio | 2.46 |
| Volatility | 1.43 |
| Rel Volume | 1.30 |
Performance History
| Week | +21.56% |
| Month | +6.28% |
| Quarter | +31.82% |
| 6 Months | -49.25% |
| YTD | +76.52% |
| Year | +70.59% |
| 3 Years | -34.09% |
| 10 Years | -84.62% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $2.03 | 668,700 |
| 2026-06-17 | $1.90 | 390,100 |
| 2026-06-16 | $1.75 | 399,200 |
| 2026-06-15 | $1.74 | 650,100 |
| 2026-06-12 | $1.76 | 437,500 |
| 2026-06-11 | $1.67 | 806,100 |
| 2026-06-10 | $1.67 | 119,300 |
| 2026-06-09 | $1.70 | 177,800 |
| 2026-06-08 | $1.69 | 162,500 |
| 2026-06-05 | $1.78 | 845,000 |
| 2026-06-04 | $1.71 | 284,000 |
| 2026-06-03 | $1.70 | 179,200 |
| 2026-06-02 | $1.71 | 481,000 |
| 2026-06-01 | $1.79 | 490,700 |
| 2026-05-29 | $1.80 | 299,000 |
| 2026-05-28 | $1.78 | 652,500 |
| 2026-05-27 | $1.73 | 429,800 |
| 2026-05-26 | $1.63 | 1,276,700 |
| 2026-05-22 | $1.96 | 1,215,500 |
| 2026-05-21 | $1.94 | 351,400 |
| 2026-05-20 | $2.00 | 556,000 |
| 2026-05-19 | $1.91 | 261,000 |
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
đ° Latest News
Analysts See Nearly 3X Upside in Pyxis Oncology (PYXS)
Insider Monkey âĸ 2026-06-10T18:22:44Z
Creative Global Technology Holdings And 2 Other Promising Penny Stocks
Simply Wall St. âĸ 2026-05-12T12:04:59Z
NanoViricidesâ Measles Treatment Granted Orphan Drug Designation by FDA
Exec Edge âĸ 2026-05-06T12:35:33Z
3 Penny Stocks With Market Caps Under $400M To Consider
Simply Wall St. âĸ 2026-04-13T18:05:13Z
3 Penny Stocks With Market Caps Over $50M To Watch
Simply Wall St. âĸ 2026-02-06T12:05:52Z
3 Promising Penny Stocks With Market Caps Up To $300M
Simply Wall St. âĸ 2026-01-07T18:05:46Z
Wall Street Set to Open Higher Thursday as Inflation Rises Less Than Expected; Jobless Claims Decline
MT Newswires âĸ 2025-12-18T14:23:13ZInvestors Await Key Inflation, Employment Data as US Futures Rise Thursday Pre-Bell
MT Newswires âĸ 2025-12-18T13:15:50Z3 Promising Penny Stocks With Over $90M Market Cap
Simply Wall St. âĸ 2025-12-09T12:05:19Z
Pyxis Oncology And 2 Other Promising Penny Stocks To Watch
Simply Wall St. âĸ 2025-11-04T12:05:12Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $2,388,000 | $475,000 | $0 | - |
| Cost Of Revenue | $2,388,000 | $475,000 | $0 | - |
| Total Revenue | $13,858,000 | $16,146,000 | $0 | $0 |
| Operating Revenue | $13,858,000 | $16,146,000 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $98,278,000 | $84,642,000 | $82,196,000 | $123,481,000 |
| Other Income Expense | $2,575,000 | $-18,038,000 | $1,776,000 | - |
| Other Non Operating Income Expenses | $2,575,000 | $2,926,000 | $1,776,000 | - |
| Net Non Operating Interest Income Expense | $3,610,000 | $7,039,000 | $6,630,000 | $2,764,000 |
| Operating Expense | $95,890,000 | $84,167,000 | $82,196,000 | $123,481,000 |
| General And Administrative Expense | $22,194,000 | $25,420,000 | $32,610,000 | $37,352,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-79,621,000 | $-77,331,000 | $-73,790,000 | $-120,717,000 |
| Net Interest Income | $3,610,000 | $7,039,000 | $6,630,000 | $2,764,000 |
| Interest Income | $3,610,000 | $7,039,000 | $6,630,000 | $2,764,000 |
| Normalized Income | $-79,621,000 | $-56,912,064 | $-73,790,000 | $-120,717,000 |
| Net Income From Continuing And Discontinued Operation | $-79,621,000 | $-77,331,000 | $-73,790,000 | $-120,717,000 |
| Total Operating Income As Reported | $-84,420,000 | $-89,460,000 | $-82,196,000 | $-123,481,000 |
| Net Income Common Stockholders | $-79,621,000 | $-77,331,000 | $-73,790,000 | $-120,717,000 |
| Net Income | $-79,621,000 | $-77,331,000 | $-73,790,000 | $-120,717,000 |
| Net Income Including Noncontrolling Interests | $-79,621,000 | $-77,331,000 | $-73,790,000 | $-120,717,000 |
| Net Income Continuous Operations | $-79,621,000 | $-77,331,000 | $-73,790,000 | $-120,717,000 |
| Pretax Income | $-78,235,000 | $-79,495,000 | $-73,790,000 | $-120,717,000 |
| Special Income Charges | $0 | $-20,964,000 | $0 | - |
| Interest Income Non Operating | $3,610,000 | $7,039,000 | $6,630,000 | $2,764,000 |
| Operating Income | $-84,420,000 | $-68,496,000 | $-82,196,000 | $-123,481,000 |
| Gross Profit | $11,470,000 | $15,671,000 | $0 | - |
| Earnings From Equity Interest | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-1.28 | $-1.32 | $-1.85 | $-3.65 |
| Basic EPS | $-1.28 | $-1.32 | $-1.85 | $-3.65 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $-545,064 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-79,909,000 | $-44,550,000 | $-80,269,000 | $-122,772,000 |
| Total Unusual Items | $0 | $-20,964,000 | $0 | - |
| Total Unusual Items Excluding Goodwill | $0 | $-20,964,000 | $0 | - |
| Reconciled Depreciation | $4,511,000 | $2,982,000 | $1,927,000 | $709,000 |
| EBITDA (Bullshit earnings) | $-79,909,000 | $-65,514,000 | $-80,269,000 | $-122,772,000 |
| EBIT | $-84,420,000 | $-68,496,000 | $-82,196,000 | $-123,481,000 |
| Diluted Average Shares | $62,143,166 | $58,445,765 | $39,904,603 | $33,033,081 |
| Basic Average Shares | $62,143,166 | $58,445,765 | $39,904,603 | $33,033,081 |
| Diluted NI Availto Com Stockholders | $-79,621,000 | $-77,331,000 | $-73,790,000 | $-120,717,000 |
| Tax Provision | $1,386,000 | $-2,164,000 | $0 | - |
| Impairment Of Capital Assets | $0 | $20,964,000 | $0 | - |
| Research And Development | $73,696,000 | $58,747,000 | $49,586,000 | $86,129,000 |
| Selling General And Administration | $22,194,000 | $25,420,000 | $32,610,000 | $37,352,000 |
| Other Gand A | $4,179,000 | $4,491,000 | $6,347,000 | $13,061,000 |
| Insurance And Claims | $4,135,000 | $5,149,000 | $5,173,000 | $5,559,000 |
| Salaries And Wages | $13,880,000 | $15,780,000 | $21,090,000 | $18,732,000 |
| Gain On Sale Of Security | - | - | - | - |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $53,408,000 | $118,151,000 | $101,396,000 | $160,824,000 |
| Total Assets | $91,520,000 | $157,181,000 | $173,726,000 | $211,379,000 |
| Total Non Current Assets | $19,415,000 | $24,741,000 | $49,122,000 | $24,767,000 |
| Goodwill And Other Intangible Assets | $0 | $2,600,000 | $24,308,000 | $0 |
| Current Assets | $72,105,000 | $132,440,000 | $124,604,000 | $186,612,000 |
| Other Current Assets | $2,490,000 | $3,276,000 | $2,822,000 | $3,941,000 |
| Restricted Cash | $1,472,000 | $1,472,000 | $1,472,000 | $1,472,000 |
| Prepaid Assets | $586,000 | $761,000 | $1,012,000 | $1,308,000 |
| Receivables | $700,000 | $0 | $21,000 | $598,000 |
| Other Receivables | $700,000 | - | - | - |
| Cash Cash Equivalents And Short Term Investments | $66,857,000 | $126,931,000 | $119,298,000 | $179,293,000 |
| Cash And Cash Equivalents | $15,422,000 | $19,473,000 | $9,664,000 | $179,293,000 |
| Other Intangible Assets | - | $2,600,000 | $24,308,000 | - |
| Accrued Interest Receivable | - | - | $21,000 | $598,000 |
| Other Non Current Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $18,673,000 | $20,200,000 | $21,331,000 | $18,921,000 |
| Long Term Debt And Capital Lease Obligation | $16,981,000 | $18,750,000 | $20,099,000 | $18,921,000 |
| Current Debt And Capital Lease Obligation | $1,692,000 | $1,450,000 | $1,232,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $38,112,000 | $36,430,000 | $48,022,000 | $50,555,000 |
| Total Non Current Liabilities Net Minority Interest | $16,981,000 | $18,750,000 | $22,263,000 | $18,921,000 |
| Current Liabilities | $21,131,000 | $17,680,000 | $25,759,000 | $31,634,000 |
| Other Current Liabilities | $431,000 | $643,000 | $356,000 | $1,091,000 |
| Payables And Accrued Expenses | $15,692,000 | $11,604,000 | $11,292,000 | $26,305,000 |
| Payables | $10,885,000 | $4,859,000 | $3,896,000 | $7,097,000 |
| Accounts Payable | $10,885,000 | $4,859,000 | $3,896,000 | $7,097,000 |
| Non Current Deferred Liabilities | - | $0 | $2,164,000 | $0 |
| Non Current Deferred Taxes Liabilities | - | $0 | $2,164,000 | $0 |
| Current Deferred Liabilities | - | $0 | $7,660,000 | $0 |
| Equity | ||||
| Common Stock Equity | $53,408,000 | $120,751,000 | $125,704,000 | $160,824,000 |
| Total Equity Gross Minority Interest | $53,408,000 | $120,751,000 | $125,704,000 | $160,824,000 |
| Stockholders Equity | $53,408,000 | $120,751,000 | $125,704,000 | $160,824,000 |
| Gains Losses Not Affecting Retained Earnings | $53,000 | $170,000 | $63,000 | $0 |
| Other Equity Adjustments | $53,000 | $170,000 | $63,000 | - |
| Retained Earnings | $-443,177,000 | $-363,556,000 | $-286,225,000 | $-212,435,000 |
| Other | ||||
| Ordinary Shares Number | $62,690,229 | $59,967,814 | $44,754,853 | $34,958,730 |
| Share Issued | $62,690,229 | $59,967,814 | $44,754,853 | $34,958,730 |
| Tangible Book Value | $53,408,000 | $118,151,000 | $101,396,000 | $160,824,000 |
| Invested Capital | $53,408,000 | $120,751,000 | $125,704,000 | $160,824,000 |
| Working Capital | $50,974,000 | $114,760,000 | $98,845,000 | $154,978,000 |
| Capital Lease Obligations | $18,673,000 | $20,200,000 | $21,331,000 | $18,921,000 |
| Total Capitalization | $53,408,000 | $120,751,000 | $125,704,000 | $160,824,000 |
| Additional Paid In Capital | $496,469,000 | $484,077,000 | $411,821,000 | $373,225,000 |
| Capital Stock | $63,000 | $60,000 | $45,000 | $34,000 |
| Common Stock | $63,000 | $60,000 | $45,000 | $34,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $16,981,000 | $18,750,000 | $20,099,000 | $18,921,000 |
| Current Capital Lease Obligation | $1,692,000 | $1,450,000 | $1,232,000 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $3,316,000 | $3,983,000 | $5,219,000 | $4,238,000 |
| Current Accrued Expenses | $4,807,000 | $6,745,000 | $7,396,000 | $19,208,000 |
| Net PPE | $19,415,000 | $22,141,000 | $24,814,000 | $24,767,000 |
| Accumulated Depreciation | $-7,007,000 | $-5,233,000 | $-3,602,000 | $-1,825,000 |
| Gross PPE | $26,422,000 | $27,374,000 | $28,416,000 | $26,592,000 |
| Leases | $10,742,000 | $10,742,000 | $10,956,000 | $530,000 |
| Other Properties | $14,652,000 | $15,603,000 | $16,337,000 | $15,849,000 |
| Machinery Furniture Equipment | $1,028,000 | $1,029,000 | $1,123,000 | $1,036,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $51,435,000 | $107,458,000 | $109,634,000 | $0 |
| Current Deferred Revenue | - | $0 | $7,660,000 | $0 |
| Treasury Shares Number | - | - | $0 | - |
| Construction In Progress | - | - | $0 | $9,177,000 |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-63,511,000 | $-57,909,000 | $-77,435,000 | $-95,734,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-63,502,000 | $-57,672,000 | $-70,709,000 | $-89,335,000 |
| Cash Flow From Continuing Operating Activities | $-63,502,000 | $-57,672,000 | $-70,709,000 | $-89,335,000 |
| Operating Gains Losses | - | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-9,000 | $-237,000 | $-6,726,000 | $-6,399,000 |
| Investing Cash Flow | $58,857,000 | $8,155,000 | $-104,849,000 | $-6,399,000 |
| Cash Flow From Continuing Investing Activities | $58,857,000 | $8,155,000 | $-104,849,000 | $-6,399,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $2,000 | $59,046,000 | $6,122,000 | $0 |
| Financing Cash Flow | $594,000 | $59,326,000 | $5,929,000 | $183,000 |
| Cash Flow From Continuing Financing Activities | $594,000 | $59,326,000 | $5,929,000 | $183,000 |
| Net Other Financing Charges | $-148,000 | $-240,000 | $-445,000 | - |
| Net Common Stock Issuance | $2,000 | $59,046,000 | $6,122,000 | $0 |
| Common Stock Issuance | $2,000 | $59,046,000 | $6,122,000 | $0 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| Interest Paid Supplemental Data | $91,000 | $10,000 | $1,000 | - |
| Income Tax Paid Supplemental Data | $1,379,000 | $164,000 | $48,000 | $17,000 |
| End Cash Position | $16,894,000 | $20,945,000 | $11,136,000 | $180,765,000 |
| Beginning Cash Position | $20,945,000 | $11,136,000 | $180,765,000 | $276,316,000 |
| Changes In Cash | $-4,051,000 | $9,809,000 | $-169,629,000 | $-95,551,000 |
| Proceeds From Stock Option Exercised | $740,000 | $520,000 | $252,000 | $183,000 |
| Net Investment Purchase And Sale | $58,866,000 | $8,392,000 | $-104,783,000 | $0 |
| Sale Of Investment | $165,871,000 | $168,510,000 | $92,048,000 | $0 |
| Purchase Of Investment | $-107,005,000 | $-160,118,000 | $-196,831,000 | $0 |
| Net PPE Purchase And Sale | $-9,000 | $-237,000 | $-6,726,000 | $-6,399,000 |
| Purchase Of PPE | $-9,000 | $-237,000 | $-6,726,000 | $-6,399,000 |
| Change In Working Capital | $1,943,000 | $-11,823,000 | $-11,664,000 | $4,501,000 |
| Change In Other Working Capital | $-71,000 | $-9,919,000 | $998,000 | - |
| Change In Other Current Liabilities | $-1,450,000 | $-1,231,000 | $2,410,000 | $4,259,000 |
| Change In Payables And Accrued Expense | $3,203,000 | $-470,000 | $-17,604,000 | $3,623,000 |
| Change In Accrued Expense | $-2,823,000 | $-1,670,000 | $-14,097,000 | $11,951,000 |
| Change In Payable | $6,026,000 | $1,200,000 | $-3,507,000 | $-8,328,000 |
| Change In Account Payable | $6,026,000 | $1,200,000 | $-3,507,000 | $-8,328,000 |
| Change In Prepaid Assets | $261,000 | $-203,000 | $2,532,000 | $-3,381,000 |
| Other Non Cash Items | $824,000 | $700,000 | $660,000 | $10,408,000 |
| Stock Based Compensation | $11,801,000 | $12,945,000 | $16,946,000 | $15,764,000 |
| Asset Impairment Charge | $0 | $20,964,000 | $0 | - |
| Amortization Of Securities | $-2,960,000 | $-6,109,000 | $-4,788,000 | $0 |
| Depreciation Amortization Depletion | $4,511,000 | $2,982,000 | $1,927,000 | $709,000 |
| Depreciation And Amortization | $4,511,000 | $2,982,000 | $1,927,000 | $709,000 |
| Net Income From Continuing Operations | $-79,621,000 | $-77,331,000 | $-73,790,000 | $-120,717,000 |
| Net Business Purchase And Sale | - | $0 | $6,660,000 | $0 |
| Sale Of Business | - | $0 | $6,660,000 | $0 |
| Purchase Of Business | - | - | - | $0 |
| Earnings Losses From Equity Investments | - | - | - | $0 |
| Gain Loss On Investment Securities | - | - | - | - |
Fetched: 2026-06-19